Unknown

Dataset Information

0

An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study).

ABSTRACT: Background: The ARROW study demonstrated that once-weekly carfilzomib and dexamethasone (wKd) therapy significantly prolonged progression-free survival compared with twice-weekly carfilzomib and dexamethasone therapy in relapsed or refractory multiple myeloma patients. Aim: To describe the treatment patterns, effectiveness and safety of wKd therapy in real-world settings in Japan. Methods: We investigated data from the medical records of 126 Japanese patients with relapsed or refractory multiple myeloma. Results: The overall response rate was 66.3%. The median progression-free survival was 9.5 months. The incidence of treatment-emergent adverse events of any grade and grade ≥3 were 45.8 and 20.8%, respectively. Conclusion: There were no new or unexpected safety signals in this study. This study demonstrated the effectiveness and safety profiles of wKd therapy in Japan.

SUBMITTER: Abe Y 

PROVIDER: S-EPMC11318723 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

<b>Background:</b> The ARROW study demonstrated that once-weekly carfilzomib and dexamethasone (wKd) therapy significantly prolonged progression-free survival compared with twice-weekly carfilzomib and dexamethasone therapy in relapsed or refractory multiple myeloma patients. <b>Aim:</b> To describe the treatment patterns, effectiveness and safety of wKd therapy in real-world settings in Japan. <b>Methods:</b> We investigated data from the medical records of 126 Japanese patients with relapsed o  ...[more]

Similar Datasets

Unknown Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
| S-EPMC8605887 | biostudies-literature
Unknown A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
| S-EPMC7898514 | biostudies-literature
Unknown A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
| S-EPMC11465039 | biostudies-literature
Unknown CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
| S-EPMC4929927 | biostudies-literature
Unknown Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.
| S-EPMC7062899 | biostudies-literature
Unknown Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.
| S-EPMC7547551 | biostudies-literature
Unknown Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
| S-EPMC6593978 | biostudies-literature
Unknown A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.
| S-EPMC5342543 | biostudies-literature
Unknown Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials.
| S-EPMC7196059 | biostudies-literature
Unknown Cardiac and renal complications of carfilzomib in patients with multiple myeloma.
| S-EPMC5738981 | biostudies-other